RU2020142530A - Множественные олигонуклеотидные фрагменты на пептидном носителе - Google Patents
Множественные олигонуклеотидные фрагменты на пептидном носителе Download PDFInfo
- Publication number
- RU2020142530A RU2020142530A RU2020142530A RU2020142530A RU2020142530A RU 2020142530 A RU2020142530 A RU 2020142530A RU 2020142530 A RU2020142530 A RU 2020142530A RU 2020142530 A RU2020142530 A RU 2020142530A RU 2020142530 A RU2020142530 A RU 2020142530A
- Authority
- RU
- Russia
- Prior art keywords
- aon
- peptide
- rxrrbr
- glu
- naturally occurring
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 2
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 36
- 238000012230 antisense oligonucleotides Methods 0.000 claims 36
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 34
- 238000000034 method Methods 0.000 claims 14
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims 6
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims 6
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 102100021158 Double homeobox protein 4 Human genes 0.000 claims 4
- 101000968549 Homo sapiens Double homeobox protein 4 Proteins 0.000 claims 4
- 102000018658 Myotonin-Protein Kinase Human genes 0.000 claims 4
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 claims 4
- 108091093037 Peptide nucleic acid Proteins 0.000 claims 4
- 108010009583 Transforming Growth Factors Proteins 0.000 claims 4
- 102000009618 Transforming Growth Factors Human genes 0.000 claims 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical group NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims 4
- 230000000295 complement effect Effects 0.000 claims 4
- 108020004999 messenger RNA Proteins 0.000 claims 4
- -1 methylene methylimino Chemical group 0.000 claims 4
- 239000002213 purine nucleotide Substances 0.000 claims 4
- 238000003776 cleavage reaction Methods 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000007017 scission Effects 0.000 claims 3
- NTPQDQNDQNWGFV-UHFFFAOYSA-N (morpholin-4-ylamino)phosphonic acid Chemical compound OP(O)(=O)NN1CCOCC1 NTPQDQNDQNWGFV-UHFFFAOYSA-N 0.000 claims 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical group NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims 2
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims 2
- 101710159080 Aconitate hydratase A Proteins 0.000 claims 2
- 101710159078 Aconitate hydratase B Proteins 0.000 claims 2
- 102100033676 CUGBP Elav-like family member 1 Human genes 0.000 claims 2
- 229930028154 D-arginine Natural products 0.000 claims 2
- 125000002038 D-arginyl group Chemical group N[C@@H](C(=O)*)CCCNC(=N)N 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 108010001483 Glycogen Synthase Proteins 0.000 claims 2
- 102100039264 Glycogen [starch] synthase, liver Human genes 0.000 claims 2
- 102100039262 Glycogen [starch] synthase, muscle Human genes 0.000 claims 2
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 claims 2
- 101000944448 Homo sapiens CUGBP Elav-like family member 1 Proteins 0.000 claims 2
- 101001036117 Homo sapiens Glycogen [starch] synthase, liver Proteins 0.000 claims 2
- 101001036130 Homo sapiens Glycogen [starch] synthase, muscle Proteins 0.000 claims 2
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims 2
- 108010006035 Metalloproteases Proteins 0.000 claims 2
- 102000005741 Metalloproteases Human genes 0.000 claims 2
- 108700011259 MicroRNAs Proteins 0.000 claims 2
- 108091092724 Noncoding DNA Proteins 0.000 claims 2
- 102000004264 Osteopontin Human genes 0.000 claims 2
- 108010081689 Osteopontin Proteins 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 102000035195 Peptidases Human genes 0.000 claims 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 2
- 102000044126 RNA-Binding Proteins Human genes 0.000 claims 2
- 101710105008 RNA-binding protein Proteins 0.000 claims 2
- 229960002684 aminocaproic acid Drugs 0.000 claims 2
- 229940000635 beta-alanine Drugs 0.000 claims 2
- 125000002091 cationic group Chemical group 0.000 claims 2
- RTINQKRHLKCKBZ-UHFFFAOYSA-N diaminophosphinic acid;morpholine Chemical group NP(N)(O)=O.C1COCCN1 RTINQKRHLKCKBZ-UHFFFAOYSA-N 0.000 claims 2
- 230000014509 gene expression Effects 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 claims 2
- 150000003212 purines Chemical class 0.000 claims 2
- 239000002719 pyrimidine nucleotide Substances 0.000 claims 2
- 150000003230 pyrimidines Chemical class 0.000 claims 2
- 102000005600 Cathepsins Human genes 0.000 claims 1
- 108010084457 Cathepsins Proteins 0.000 claims 1
- 229930182847 D-glutamic acid Natural products 0.000 claims 1
- 125000004077 D-glutamic acid group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C([H])([H])C(N([H])[H])=O 0.000 claims 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims 1
- 102000001039 Dystrophin Human genes 0.000 claims 1
- 108010069091 Dystrophin Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102000004142 Trypsin Human genes 0.000 claims 1
- 108090000631 Trypsin Proteins 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 235000019833 protease Nutrition 0.000 claims 1
- 235000019419 proteases Nutrition 0.000 claims 1
- 239000012588 trypsin Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462002296P | 2014-05-23 | 2014-05-23 | |
| US62/002,296 | 2014-05-23 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016150629A Division RU2739987C2 (ru) | 2014-05-23 | 2015-05-22 | Множественные олигонуклеотидные фрагменты на пептидном носителе |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2020142530A true RU2020142530A (ru) | 2021-04-26 |
Family
ID=53366294
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020142530A RU2020142530A (ru) | 2014-05-23 | 2015-05-22 | Множественные олигонуклеотидные фрагменты на пептидном носителе |
| RU2016150629A RU2739987C2 (ru) | 2014-05-23 | 2015-05-22 | Множественные олигонуклеотидные фрагменты на пептидном носителе |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016150629A RU2739987C2 (ru) | 2014-05-23 | 2015-05-22 | Множественные олигонуклеотидные фрагменты на пептидном носителе |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20170182171A1 (2) |
| EP (1) | EP3151841B1 (2) |
| JP (2) | JP6825914B2 (2) |
| KR (1) | KR102487942B1 (2) |
| CN (1) | CN106459975B (2) |
| AR (1) | AR101542A1 (2) |
| AU (1) | AU2015263963B2 (2) |
| BR (1) | BR112016027236A2 (2) |
| CA (1) | CA2949104C (2) |
| IL (1) | IL249064B (2) |
| MX (1) | MX381946B (2) |
| RU (2) | RU2020142530A (2) |
| SG (2) | SG10202004611SA (2) |
| TW (1) | TWI726844B (2) |
| WO (1) | WO2015179742A1 (2) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106459975B (zh) | 2014-05-23 | 2020-03-27 | 建新公司 | 肽载体上的多个寡核苷酸部分 |
| EP3808849A1 (en) | 2017-08-03 | 2021-04-21 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| JP7441455B2 (ja) * | 2017-09-22 | 2024-03-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト | 筋ジストロフィーの処置のためのチオモルホリノオリゴヌクレオチド |
| US11897911B2 (en) | 2018-03-07 | 2024-02-13 | Sanofi | Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same |
| US10758629B2 (en) * | 2018-05-29 | 2020-09-01 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| CN114728999A (zh) * | 2019-09-05 | 2022-07-08 | 赛诺菲 | 含有核苷酸类似物的寡核苷酸 |
| WO2021211572A1 (en) * | 2020-04-14 | 2021-10-21 | Oregon State University | Antisense therapeutics for the treatment of coronavirus |
| US20250011777A1 (en) * | 2021-09-03 | 2025-01-09 | Sarepta Therapeutics, Inc. | Delivery of anitsense oligomers by mirror image peptides |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995006056A1 (en) * | 1993-08-20 | 1995-03-02 | University Of Medicine & Dentistry Of New Jersey | Bridged polycationic polymer-oligonucleotide conjugates and methods for preparing same |
| DE19935302A1 (de) | 1999-07-28 | 2001-02-08 | Aventis Pharma Gmbh | Konjugate und Verfahren zu deren Herstellung sowie deren Verwendung zum Transport von Molekülen über biologische Membranen |
| US7468418B2 (en) | 2003-04-29 | 2008-12-23 | Avi Biopharma., Inc. | Compositions for enhancing transport of molecules into cells |
| WO2009005793A2 (en) | 2007-06-29 | 2009-01-08 | Avi Biopharma, Inc. | Tissue specific peptide conjugates and methods |
| US20100016215A1 (en) * | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| WO2009144481A2 (en) | 2008-05-30 | 2009-12-03 | Isis Innovation Limited | Conjugates for delivery of biologically active compounds |
| WO2009147368A1 (en) | 2008-06-04 | 2009-12-10 | Medical Research Council | Peptides |
| BR122020021379B1 (pt) | 2008-10-24 | 2021-05-11 | Sarepta Therapeutics, Inc. | oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular |
| WO2012177639A2 (en) * | 2011-06-22 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Bioprocessing and bioproduction using avian cell lines |
| AU2012308320C1 (en) * | 2011-09-14 | 2018-08-23 | Translate Bio Ma, Inc. | Multimeric oligonucleotide compounds |
| EP2900821B1 (en) * | 2012-09-25 | 2020-04-01 | Genzyme Corporation | Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy |
| CA2935426C (en) * | 2014-01-30 | 2023-07-25 | F. Hoffmann-La Roche Ag | Polyoligomer compound with biocleavable conjugates for reducing or inhibiting expression of a nucleic acid target |
| CN106459975B (zh) | 2014-05-23 | 2020-03-27 | 建新公司 | 肽载体上的多个寡核苷酸部分 |
-
2015
- 2015-05-22 CN CN201580027369.4A patent/CN106459975B/zh active Active
- 2015-05-22 EP EP15727795.5A patent/EP3151841B1/en active Active
- 2015-05-22 SG SG10202004611SA patent/SG10202004611SA/en unknown
- 2015-05-22 RU RU2020142530A patent/RU2020142530A/ru unknown
- 2015-05-22 AU AU2015263963A patent/AU2015263963B2/en not_active Ceased
- 2015-05-22 BR BR112016027236A patent/BR112016027236A2/pt not_active Application Discontinuation
- 2015-05-22 JP JP2016567889A patent/JP6825914B2/ja not_active Expired - Fee Related
- 2015-05-22 TW TW104116447A patent/TWI726844B/zh not_active IP Right Cessation
- 2015-05-22 WO PCT/US2015/032142 patent/WO2015179742A1/en not_active Ceased
- 2015-05-22 CA CA2949104A patent/CA2949104C/en active Active
- 2015-05-22 US US15/313,405 patent/US20170182171A1/en not_active Abandoned
- 2015-05-22 KR KR1020167035607A patent/KR102487942B1/ko active Active
- 2015-05-22 MX MX2016015156A patent/MX381946B/es unknown
- 2015-05-22 AR ARP150101604A patent/AR101542A1/es unknown
- 2015-05-22 SG SG11201608880VA patent/SG11201608880VA/en unknown
- 2015-05-22 RU RU2016150629A patent/RU2739987C2/ru active
-
2016
- 2016-11-20 IL IL249064A patent/IL249064B/en unknown
-
2019
- 2019-02-01 US US16/265,883 patent/US11103587B2/en not_active Expired - Fee Related
-
2021
- 2021-01-13 JP JP2021003149A patent/JP7269968B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2016015156A (es) | 2017-03-27 |
| EP3151841B1 (en) | 2022-10-19 |
| CN106459975B (zh) | 2020-03-27 |
| SG11201608880VA (en) | 2016-11-29 |
| MX381946B (es) | 2025-03-13 |
| AU2015263963B2 (en) | 2021-02-18 |
| AR101542A1 (es) | 2016-12-28 |
| JP2021063128A (ja) | 2021-04-22 |
| BR112016027236A2 (pt) | 2017-10-17 |
| TW201617373A (zh) | 2016-05-16 |
| KR102487942B1 (ko) | 2023-01-11 |
| CN106459975A (zh) | 2017-02-22 |
| JP2017517253A (ja) | 2017-06-29 |
| CA2949104C (en) | 2023-09-26 |
| US20190388547A1 (en) | 2019-12-26 |
| CA2949104A1 (en) | 2015-11-26 |
| US11103587B2 (en) | 2021-08-31 |
| RU2016150629A3 (2) | 2018-12-24 |
| RU2016150629A (ru) | 2018-06-25 |
| JP6825914B2 (ja) | 2021-02-03 |
| EP3151841A1 (en) | 2017-04-12 |
| JP7269968B2 (ja) | 2023-05-09 |
| IL249064B (en) | 2021-07-29 |
| SG10202004611SA (en) | 2020-06-29 |
| AU2015263963A1 (en) | 2016-12-01 |
| IL249064A0 (en) | 2017-01-31 |
| TWI726844B (zh) | 2021-05-11 |
| WO2015179742A1 (en) | 2015-11-26 |
| KR20170005118A (ko) | 2017-01-11 |
| RU2739987C2 (ru) | 2020-12-30 |
| US20170182171A1 (en) | 2017-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020142530A (ru) | Множественные олигонуклеотидные фрагменты на пептидном носителе | |
| US20210371861A1 (en) | Multi-Targeting Nucleic Acid Constructs Composed Of Multiple Oligonucleotides That Modulate Gene Expression Through Complimentary Interactions With Targets | |
| Hussain et al. | A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides | |
| JP2015529469A5 (2) | ||
| Ganesh et al. | Peptide nucleic acids analogs and derivatives | |
| Brognara et al. | Peptide nucleic acids targeting miR-221 modulate p27Kip1 expression in breast cancer MDA-MB-231 cells | |
| Summerton | Morpholinos and PNAs compared | |
| Moccia et al. | Insights on chiral, backbone modified peptide nucleic acids: properties and biological activity | |
| WO2006078217A1 (en) | COMPLEX CONTAINING SiRNA, ShRNA OR ANTISENSE MOLECULE AND FUNCTIONAL ENTITY, FOR IMPROVED SPECIFICITY AND DELIVERY | |
| JP2013510584A5 (2) | ||
| JP2007500018A5 (2) | ||
| US9725715B2 (en) | Signal activatable constructs and related components compositions methods and systems | |
| US20100240058A1 (en) | MicroRNA Antisense PNAs, Compositions Comprising the Same, and Methods for Using and Evaluating the Same | |
| US20210130822A1 (en) | Antisense oligomer compounds | |
| Patutina et al. | Peptide-oligonucleotide conjugates exhibiting pyrimidine-X cleavage specificity efficiently silence miRNA target acting synergistically with RNase H | |
| US20220411841A1 (en) | Methods of synthesizing rna molecules | |
| JPWO2019074110A1 (ja) | 一本鎖核酸分子およびその製造方法 | |
| US20210269851A1 (en) | Massively parallel discovery methods for oligonucleotide therapeutics | |
| JP2017517253A5 (2) | ||
| Arzumanov et al. | A structure-activity study of the inhibition of HIV-1 Tat-dependent trans-activation by mixmer 2′-O-methyl oligoribonucleotides containing locked nucleic acid (LNA), α-L-LNA, or 2′-thio-LNA residues | |
| Sazani et al. | Effects of base modifications on antisense properties of 2′-O-methoxyethyl and PNA oligonucleotides | |
| WO2021231305A3 (en) | Viral delivery vehicle selection | |
| US20260062703A1 (en) | Delivery of RNA Therapeutics Using Circular Prodrug Nucleic Acids | |
| Patil et al. | Recognition of RNA sequence and structure by duplex and triplex formation: targeting miRNA and pre-miRNA | |
| JP2025513740A5 (2) |